
Cocrystal Pharma, Inc.
94
Recent developments highlight wider Q3 losses driven by norovirus challenge study costs, completion of dosing in the Phase 1b norovirus study, leadership changes, and anticipation of norovirus data near year-end 2026.
- Cocrystal Pharma posted a wider Q3 loss led by costs associated with the norovirus challenge study [N1].
- The Q3 loss widened due to higher costs, with norovirus data expected near year-end 2026 [N2].
- The company announced dosing of the last subject in the Phase 1b norovirus study in September 2026 [N3].
- James Sapirstein was named CEO in June 2026, with the stock rising in pre-market trading [N4].
- CDI-988 secured FDA Fast Track designation for prevention and treatment of norovirus in April 2026 [N6].
- Positive Phase 1 study results for CDI-988 were reported in April 2026 [N5].
- The company narrowed its loss in Q2 2025 [N7].
- Promising results for CDI-988 as treatment for the rising norovirus GII.17 strain were announced in April 2025 [N8].
Cocrystal Pharma, Inc. operates as a single business entity focused on discovering and developing small molecule antiviral therapeutics targeting RNA viruses responsible for serious and chronic diseases. The company employs a proprietary structure-based drug discovery platform integrating computational chemistry, X-ray crystallography, and enzymology to design drugs that inhibit viral replication enzymes with high specificity and broad-spectrum activity. Their pipeline includes CC-42344, a PB2 inhibitor for influenza A, and CDI-988, a pan-viral protease inhibitor targeting norovirus and coronaviruses including SARS-CoV-2 variants. The company aims to develop drugs with high barriers to resistance, broad strain coverage, novel mechanisms, favorable safety profiles, and convenient administration routes such as oral or inhaled formulations. Recent clinical progress includes Phase 1b norovirus challenge studies and positive Phase 1 safety data for CDI-988. Financially, the company reported a net loss of $3.444 million for Q3 2026, with cash and equivalents of $7.025 million as of December 31, 2025, and a current ratio of 1.72 as of September 30, 2026. The company also recognizes revenue from government contracts and has ongoing disputes related to a Phase 2a influenza study.
Cocrystal Pharma, Inc. is a clinical-stage biotech company developing novel antiviral therapeutics using proprietary structure-based drug design technology targeting RNA viruses including influenza, norovirus, and coronaviruses. The company has multiple drug candidates in preclinical and clinical stages, notably CC-42344 for influenza A and CDI-988 for norovirus and coronaviruses. CDI-988 has received FDA Fast Track designation and is in Phase 1b challenge studies. Financially, as of September 30, 2026, the company reported $7.025 million in cash and equivalents, a current ratio of 1.72, and a net loss of $3.444 million for Q3 2026. Recent news highlights include wider Q3 losses driven by norovirus study costs and leadership changes. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company's proprietary drug discovery platform leverages advanced structural biology and computational methods to design antiviral drugs with broad-spectrum activity and high barriers to resistance. Positive Phase 1 clinical results for CDI-988 and FDA Fast Track designation support its potential as a novel oral pan-viral antiviral for norovirus and coronaviruses. The pipeline includes promising candidates for influenza A with novel mechanisms of action. The company's ability to target conserved viral enzymes may enable development of therapies effective against multiple viral strains and resistant variants, addressing significant unmet medical needs.
Clinical development risks include the failure of key studies to demonstrate efficacy or safety, as evidenced by the low infectivity and unresolved dispute in the Phase 2a influenza study. The company faces financial constraints with net losses and limited cash reserves, which may impact its ability to fund ongoing and future clinical trials. Regulatory risks and competition from established antiviral therapies and emerging treatments also pose challenges. Additionally, the company's reliance on government contracts and external CROs introduces operational risks, including disputes and delays.
Cocrystal Pharma's moat derives from its proprietary structure-based drug discovery platform that integrates Nobel Prize-winning expertise, computational chemistry, and X-ray crystallography to design antiviral therapeutics targeting highly conserved viral replication enzymes. This approach aims to create broad-spectrum antiviral drugs with high barriers to resistance, addressing limitations of existing therapies that face viral mutation challenges. The company's focus on conserved viral enzyme targets and advanced drug design techniques differentiates it from traditional empirical medicinal chemistry approaches, potentially enabling development of novel, effective antiviral drugs against multiple RNA viruses including influenza, norovirus, and coronaviruses.
• Clinical Development Risk: Key clinical trials may fail to demonstrate efficacy or safety, potentially delaying or halting drug development programs.
• Financial Risk: The company reports net losses and has limited cash reserves, which may constrain its ability to finance ongoing research and development activities.
• Regulatory Risk: Approval of antiviral drugs depends on regulatory authorities; delays or denials could impact commercialization timelines.
• Operational Risk: Disputes with contract research organizations and reliance on external partners may cause delays or increased costs.
• Competitive Risk: Competition from existing antiviral therapies and new entrants may limit market opportunities for the company's drug candidates.
Business trends: Continued development of broad-spectrum antiviral candidates targeting influenza, norovirus, and coronaviruses with focus on high barrier to resistance and broad strain coverage.
Execution milestones: Completion of Phase 1b norovirus challenge study, resolution of influenza Phase 2a study dispute, and advancement of clinical programs including regulatory interactions.
Key risks: Clinical trial outcomes, financial resource constraints, regulatory approvals, operational disputes with CROs, and competitive antiviral market dynamics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics targeting serious and chronic viral diseases including influenza, norovirus, coronaviruses (including SARS-CoV-2), respiratory viruses, and hepatitis C virus (HCV).
- The company uses a proprietary structure-based drug design platform integrating computational chemistry, medicinal chemistry, X-ray crystallography, and enzymology to develop small molecule antiviral drugs targeting viral replication enzymes with high specificity and broad-spectrum activity.
- Their technology targets highly conserved viral enzyme regions to achieve a high barrier to drug resistance and broad effectiveness across viral strains and subtypes.
- Cocrystal Pharma's pipeline includes multiple antiviral candidates: CC-42344 for influenza A (oral and inhaled formulations) and CDI-988, a pan-viral protease inhibitor targeting norovirus and coronaviruses, including SARS-CoV-2 variants.
- CC-42344 showed promising preclinical antiviral activity against influenza A strains, including resistant and pandemic strains, but a Phase 2a human challenge study had low infectivity, leading to a dispute with the CRO and plans to continue development subject to resolution or new studies.
- CDI-988 has completed Phase 1 studies demonstrating favorable safety, tolerability, and pharmacokinetics, and has received FDA Fast Track designation for prevention and treatment of norovirus.
- A Phase 1b norovirus challenge study with CDI-988 commenced at Emory University School of Medicine with endpoints including reduction in clinical symptoms and viral shedding.
- The company operates as a single business entity and focuses on oral, inhaled, or injectable administration routes for its drug candidates.
- Financial snapshot as of September 30, 2026: cash and equivalents of $7.025 million (as of December 31, 2025), current assets of $5.513 million, current liabilities of $3.202 million, resulting in a current ratio of 1.72 and a cash ratio of 2.5.
- Revenue recognized from a government SBIR Phase I contract with NIAID was $105,000 for Q2 2026 and $435,000 for the nine months ended September 30, 2026.
- Net loss for Q3 2026 was $3.444 million with basic and diluted EPS of -$0.20 per share.
- The company had 19.26 million shares outstanding as of September 30, 2026, and completed a $5 million equity raise in July 2026 at $0.9134 per share.
- Recent leadership change: James Sapirstein was named CEO in June 2026.
- Recent clinical and operational updates include dosing the last subject in the Phase 1b norovirus study (September 2026), wider Q3 loss driven by norovirus challenge study costs (November 2026), and anticipation of norovirus data near year-end 2026.
- The company has ongoing disputes related to the influenza Phase 2a study with the CRO and is pursuing arbitration.
- Stock-based compensation plans include a 2025 Equity Incentive Plan with 1.66 million shares available for future grants as of September 30, 2026.
- The company focuses on developing antiviral drugs with high barriers to resistance, broad strain coverage, novel mechanisms, favorable safety profiles, and convenient administration routes.
- The company has reported positive Phase 1 results for CDI-988 and promising preclinical data for CC-42344 against avian influenza strains.
- The company recognizes revenue over time for government contracts and expenses research and development costs as incurred.
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-16 | www.nasdaq.com | Cocrystal Pharma Posts Wider Q3 Loss, Led By Norovirus Challenge Study Costs | https://www.nasdaq.com/articles/cocrystal-pharma-posts-wider-q3-loss-led-norovirus-challenge-study-costs
- N2 | 2026-11-16 | www.nasdaq.com | Cocrystal Q3 Loss Widens On Higher Costs; Norovirus Data Expected Near Year-End | https://www.nasdaq.com/articles/cocrystal-q3-loss-widens-higher-costs-norovirus-data-expected-near-year-end
- N3 | 2026-09-09 | www.nasdaq.com | Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Norovirus Study | https://www.nasdaq.com/articles/cocrystal-pharma-announces-last-subject-dosed-phase-1b-norovirus-study
- N4 | 2026-06-03 | www.nasdaq.com | Cocrystal Pharma Names James Sapirstein CEO, Stock Up In Pre-market | https://www.nasdaq.com/articles/cocrystal-pharma-names-james-sapirstein-ceo-stock-pre-market
- N5 | 2026-04-04 | www.nasdaq.com | Cocrystal Pharma Reports Positive Phase 1 Study Results | https://www.nasdaq.com/articles/cocrystal-pharma-reports-positive-phase-1-study-results
- N6 | 2026-04-02 | www.nasdaq.com | Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus | https://www.nasdaq.com/articles/cocrystal-pharmas-cdi-988-secures-fda-fast-track-designation-prevent-and-treat-norovirus
- N7 | 2025-08-14 | www.nasdaq.com | Cocrystal Pharma Narrows Loss in Q2 | https://www.nasdaq.com/articles/cocrystal-pharma-narrows-loss-q2
- N8 | 2025-04-24 | www.nasdaq.com | Cocrystal Pharma Announces Promising Results for CDI-988 as Treatment for Rising Norovirus GII.17 Strain | https://www.nasdaq.com/articles/cocrystal-pharma-announces-promising-results-cdi-988-treatment-rising-norovirus-gii17
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


